EN | TR
E-ISSN: 3061-9947
Analysis of Demographic and Disease Characteristics of Patients with Chronic Myeloid Leukemia: A Single Centre Retrospective Analysis
PDF
Cite
Share
Request
Original Article
VOLUME: 55 ISSUE: 1
P: 43-51
2022

Analysis of Demographic and Disease Characteristics of Patients with Chronic Myeloid Leukemia: A Single Centre Retrospective Analysis

Acta Haematol Oncol Turc 2022;55(1):43-51
DOI: 10.5505/aot.2022.08831
Mesut Tığlıoğlu 1
Murat Albayrak 1
Abdulkerim Yıldız 2
Pınar Tığlıoğlu 1
Buğra Sağlam 1
Fatma Yılmaz 1
Merih Reis Aras 1
Umit Yavuz Malkan 1
Senem Maral 1
1. University Of Health Sciences, Diskapi Yildirim Beyazit Training And Research Hospital, Department Of Hematology, Ankara, Turkey
2. Hitit University, Department Of Hematology, Corum, Turkey
3.
No information available.
No information available
Received Date: 2021-05-23T17:42:41
Accepted Date: 2022-03-31T17:36:55
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder, characterized by overproduction of cells of the myeloid series with the presence of the Philadelphia chromosome (Ph). With the development of tyrosine kinase inhibitors (TKIs), treatment options for CML have changed significantly. A key role in assessing the survival and prognosis of CML patients is the reduction of the BCR-ABL burden with appropriate treatment in defined time. The aim of this study was to analyze the clinical and demographic characteristics of CML patients, as well as their treatment efficacy, side-effect profiles, treatment resistance and survival.

METHODS

This retrospective study was conducted on patients diagnosed with BCR-ABL positive CML in the Hematology Department of our hospital between 2010 and 2020. The clinical and demographic characteristics of CML patients were analyzed together with treatment efficacy, side-effects, resistance to treatment, possible complications and survival.

RESULTS

Evaluation was made of a total of 59 patients, with the mean age of 55.59 ± 14.48 years, and median total follow-up period of 33.9 [0.2-172.0] months. All patients were given imatinib as the first-line treatment. 2 patients were included in a trial of imatinib cessation at another center. At 12 months after imatinib treatment, 53.3% patients achieved major molecular response (BCR ABL <0.1). As second generation TKIs, dasatinib was preferred in 14 (46.7%) patients and nilotinib was preferred in 15 patients (50%). At 12 months after 2nd line TKI treatment, 77.8% patients achieved major molecular response (BCR ABL <0.1). Blastic transformation was detected in 3 patients during follow-up.

DISCUSSION AND CONCLUSION

The results of the current study demonstrated that treatment options, response rates and side-effects were all comparable with the results of other real-world studies. Larger patient-based studies are needed to cover the course of the disease and to better manage these patients.